Company Profiles ENVIGO
Envigo offers a full range of bioanalytical services; from characterized assays to meet pre-GLP lead optimization needs, to full regulatory compliance supporting Safety Assessment and Clinical trials. We have over 35 years’ experience in successful bioanalytical support with extensive familiarity in the assay development, validation and analysis of small molecules, peptides and biologics. We also have more than 15 years of experience of utilizing biomarkers in clinical and non-clinical development that we apply to drug development programs. Our Clinical and Translational Sciences group is a global resource with more than 100 experienced analytical scientists, many with experience in translating non-clinical biomarkers into clinical programs, and we maintain one of the industry’s most robust catalogues of biomarkers across all technology platforms; all of which are validated to industry best practice.
Contact details Envigo Woolley Road Alconbury Huntingdon, Cambridgeshire PE28 4HS UK
www.envigo.com/
ALTASCIENCES
Altasciences Clinical Research encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, as well as Algorithme Pharma USA in Fargo, ND, thereby making it one of the largest early phase clinical CROs in North America.
Contact details Altasciences 575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada Tel.: +1 450 973 6077
www.altasciences.com/
With over 25 years of industry experience, Altasciences provides early phase clinical development services to an international customer base of biopharmaceutical and gen- eric companies. Altasciences’ full service solutions offering in this critical stage of drug development includes medical writing, biostatistics, data management and bioanalysis.
future science group
www.future-science.com S107
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117
